• Vetiranary Medicine
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Hot Literature: Lyme borreliosis in man and his best friend

September 1, 2010
Avi Blake, DVM

A workshop at the Centers for Disease Control and Prevention brought together specialists in veterinary parasitology and human internal medicine and vector-borne infectious disease to address Lyme borreliosis.

As pet owner awareness of zoonotic diseases increases, so does collaborative research between veterinarians and physicians. A workshop at the Centers for Disease Control and Prevention (CDC) brought together specialists in veterinary parasitology and human internal medicine and vector-borne infectious disease to address Lyme borreliosis. These experts summarized some recent study findings and the similarities and differences between the disease in people and dogs in the United States.

Transmission and clinical signs

The causative agent of Lyme disease, Borrelia burgdorferi, is transmitted by certain species of ixodid ticks. People are usually infected by the bite of an infected tick in the nymph stage of these ticks' three-host life cycle, whereas dogs are primarily infected by the bite of adult ticks. The primary reservoir host is the white-footed mouse, although other small mammals, such as shrews and chipmunks, have recently been suggested as potential reservoir hosts.

Symptoms in people usually develop shortly after infection, often before seroconversion. About 70% to 80% of infected people develop a characteristic rash, called erythema migrans, at the site of the tick bite. This rash can be followed by flu-like symptoms and, chronically, by arthritis, carditis, and neurologic disease. Infected dogs do not develop erythema migrans, and most infected dogs do not develop any clinical signs of Lyme borreliosis. Dogs that do develop clinical signs typically do so weeks or months after infection. Common signs include polyarthritis, anorexia, and lymphadenopathy. Dogs may also develop a glomerulonephritis syndrome. The prognosis for dogs that develop this Lyme nephropathy is poor.

Diagnosis, treatment, and prevention

Serodiagnosis remains the best way to confirm a presumed diagnosis of Lyme borreliosis in a laboratory, but the disease is definitively diagnosed through a combination of obtaining an extensive history that includes travel history; the clinician's knowledge of the disease's epidemiology; and laboratory and clinical findings. Testing people for Lyme borreliosis relies on a two-tier approach. Samples that have a positive or an indeterminate result on an initial IgM or IgG antibody detection test are submitted for Western blot testing. This method has a high sensitivity and positive predictive value in people.

Advertisement

Since most dogs have seroconverted by the time clinical signs are seen, a patient-side assay specific for the C6 peptide of the infectious organism is reliable for diagnosis and for evaluating response to treatment, but it cannot distinguish between dogs with active infection and those that have been exposed but have not developed clinical disease.

The recommended treatment for Lyme borreliosis in dogs and people is doxycycline. Beta-lactam antibiotics are also effective against B. burgdorferi. However, antibiotics in the penicillin family are not effective against other rickettsial pathogens that are common coinfections in dogs and people with Lyme borreliosis. One course of antibiotic treatment is adequate and is most effective when initiated early in the course of the disease. Dogs and people are susceptible to reinfection with subsequent exposure to B. burgdorferi.

No vaccine is available for people, but dogs may obtain an effective level of protection by a program of vaccination in endemic areas. The mainstay of prevention for people and dogs is still considered to be limiting exposure to infected ticks. Environmental and tick habitat management, prompt tick removal, and the use of repellents for people and acaricides for dogs are primary control and prevention recommendations.

Man's best friend

In fact, routinely using acaricides and insecticides on dogs has been shown to decrease the incidence of other diseases, including visceral leishmaniasis in children in endemic areas and ehrlichiosis in dogs. Although this has not been studied for Lyme borreliosis, because acaricides given routinely to dogs target primarily the adult stages of ticks, the reproductively active tick population in the local environment may be reduced, thereby protecting human health by lowering the risk of exposure to infected ixodid nymphs.

In general, wide-spread testing has shown that exposure in dogs correlates to the geographical distribution of exposure in people. The experts at the CDC workshop thought that monitoring antibody responses in dogs may help identify when B. burgdorferi begins to populate nonendemic locations. In this way, they thought that dogs could serve as sentry animals, further helping to protect human health.

Little SE, Heise SR, Blagburn BL, et al. Lyme borreliosis in dogs and humans in the USA. Trends Parasitol 2010;26(4):213-218.

For a link to the abstract, click here.

Related Content:

Parasitology
Unusual parasite strain kills 4 California sea otters
Unusual parasite strain kills 4 California sea otters
Traditional and holistic treatments for giardia
Traditional and holistic treatments for giardia
Guide offers help for navigating flea and tick season
Guide offers help for navigating flea and tick season

Advertisement

Latest News

Managing wounds in pet patients

Spectrum of care: protocols to support pet owners’ budgets

How to support women while still running a successful business

The Vets expands to Raleigh, NC

View More Latest News
Advertisement